Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem

Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem

Disease- and treatment-mediated immunodeficiency might render SARS-CoV-2 vaccines less effective in patients with hematologic diseases. We performed a prospective non-interventional study to evaluate humoral response after one and two doses of mRNA-1273, BNT162b2, or ChAdOx1 nCoV-19 vaccine in 118 p...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron: Zrinka Sertić, Marko Lucijanić, Sandra Bašić-Kinda, Ranka Serventi Seiwerth, Vlatka Periša, Dubravka Sertić, Božena Coha, Dražen Pulanić, Zinaida Perić, Lana Desnica, Mirta Mikulić, Marijo Vodanović, Ivo Radman-Livaja, Dragana Šegulja, Dunja Rogić, Toni Valković, Igor Aurer, Nadira Duraković
Fformat: Erthygl
Iaith:English
Cyhoeddwyd: MDPI AG 2022-11-01
Cyfres:Biomedicines
Pynciau:
SARS-CoV-2 vaccination
COVID-19
chronic myeloproliferative neoplasms
chronic myeloid leukemia
non-Hodgkin’s lymphoma
chronic lymphocytic leukemia
Mynediad Ar-lein:https://www.mdpi.com/2227-9059/10/11/2892

Rhyngrwyd

https://www.mdpi.com/2227-9059/10/11/2892

Eitemau Tebyg